Page 176 - Read Online

Nag et al. J Cancer Metastasis Treat 2020;6:16 I http://dx.doi.org/10.20517/2394-4722.2020.23 Page 13 of 13

60. Liang JX, Ning Z, Gao W, Ling J, Wang AM, et al. Ubiquitinspecific protease 22induced autophagy is correlated with poor prognosis of
pancreatic cancer. Oncol Rep 2014;32:2726-34.
61. Kosinsky RL, Helms M, Zerche M, Wohn L, Dyas A, et al. USP22-dependent HSP90AB1 expression promotes resistance to HSP90
inhibition in mammary and colorectal cancer. Cell Death Dis 2019;10:911.
62. Yang DD, Cui BB, Sun LY, Zheng HQ, Huang Q, et al. The co-expression of USP22 and BMI-1 may promote cancer progression and
predict therapy failure in gastric carcinoma. Cell Biochem Biophys 2011;61:703-10.
63. Yuan X, Wang H, Xu A, Zhu X, Zhan Y, et al. Ubiquitin-specific peptidase 22 promotes proliferation and metastasis in human colon
cancer. Oncol Lett 2019;18:5567-76.
64. Tang B, Tang F, Li B, Yuan S, Xu Q, et al. High USP22 expression indicates poor prognosis in hepatocellular carcinoma. Oncotarget
2015;6:12654-67.
65. Wang H, Li YP, Chen JH, Yuan SF, Wang L, et al. Prognostic significance of USP22 as an oncogene in papillary thyroid carcinoma.
Tumour Biol 2013;34:1635-9.
66. Hong A, Lee JE, Chung KC. Ubiquitin-specific protease 22 (USP22) positively regulates RCAN1 protein levels through RCAN1 de-
ubiquitination. J Cell Physiol 2015;230:1651-60.
67. Zhou D, Liu P, Sun DW, Chen ZJ, Hu J, et al. USP22 down-regulation facilitates human retinoblastoma cell aging and apoptosis via
inhibiting TERT/P53 pathway. Eur Rev Med Pharmacol Sci 2017;21:2785-92.
68. Melo-Cardenas J, Xu Y, Wei J, Tan C, Kong S, et al. USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation
through a PU.1-dependent mechanism. Blood 2018;132:423-34.
69. Kosinsky RL, Zerche M, Saul D, Wang X, Wohn L, et al. USP22 exerts tumor-suppressive functions in colorectal cancer by decreasing
mTOR activity. Cell Death Differ 2020;27:1328-40.
70. Cato L, de Tribolet-Hardy J, Lee I, Rottenberg JT, Coleman I, et al. ARv7 represses tumor-suppressor genes in castration-resistant prostate
cancer. Cancer Cell 2019;35:401-13.e6.
71. Sharp A, Coleman I, Yuan W, Sprenger C, Dolling D, et al. Androgen receptor splice variant-7 expression emerges with castration
resistance in prostate cancer. J Clin Invest 2019;129:192-208.
72. Abida W, Cyrta J, Heller G, Prandi D, Armenia J, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl
Acad Sci U S A 2019;116:11428-36.
73. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, et al. Analysis of gene expression identifies candidate markers and
pharmacological targets in prostate cancer. Cancer Res 2001;61:5974-8.
74. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, et al. Gene expression analysis of human prostate carcinoma during hormonal
therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217-27.
75. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, et al. The mutational landscape of lethal castration-resistant prostate
cancer. Nature 2012;487:239-43.
76. Nelson WG, De Marzo AM, Yegnasubramanian S. USP2a activation of MYC in prostate cancer. Cancer Discov 2012;2:206-7.
77. Priolo C, Tang D, Brahamandan M, Benassi B, Sicinska E, et al. The isopeptidase USP2a protects human prostate cancer from apoptosis.
Cancer Res 2006;66:8625-32.
78. Morra F, Merolla F, Napolitano V, Ilardi G, Miro C, et al. The combined effect of USP7 inhibitors and PARP inhibitors in hormone-
sensitive and castration-resistant prostate cancer cells. Oncotarget 2017;8:31815-29.
79. Wang Z, Kang W, You Y, Pang J, Ren H, et al. USP7: novel drug target in cancer therapy. Front Pharmacol 2019;10:427.
80. Lu Y, Bedard N, Chevalier S, Wing SS. Identification of distinctive patterns of USP19-mediated growth regulation in normal and
malignant cells. PLoS One 2011;6:e15936.
81. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat
Rev Cancer 2008;8:253-67.
82. McClurg UL, Azizyan M, Dransfield DT, Namdev N, Chit N, et al. The novel anti-androgen candidate galeterone targets deubiquitinating
enzymes, USP12 and USP46, to control prostate cancer growth and survival. Oncotarget 2018;9:24992-5007.
83. Geng L, Chen X, Zhang M, Luo Z. Ubiquitin-specific protease 14 promotes prostate cancer progression through deubiquitinating the
transcriptional factor ATF2. Biochem Biophys Res Commun 2020;524:16-21.
84. Dirac AM, Bernards R. The deubiquitinating enzyme USP26 is a regulator of androgen receptor signaling. Mol Cancer Res 2010;8:844-
54.
85. Guo F, Zhang C, Wang F, Zhang W, Shi X, et al. Deubiquitinating enzyme USP33 restrains docetaxel-induced apoptosis via stabilising
the phosphatase DUSP1 in prostate cancer. Cell Death Differ 2019; doi: 10.1038/s41418-019-0473-8.
86. Zhang J, Wang J, Luan T, Zuo Y, Chen J, et al. Deubiquitinase USP9X regulates the invasion of prostate cancer cells by regulating the
ERK pathway and mitochondrial dynamics. Oncol Rep 2019;41:3292-304.
87. Zhou X, Gan L, Liu J, Xie X, Wang T, et al. Pirarubicin reduces USP22 expression by inhibiting CREB-1 phosphorylation in HeLa cells.
Exp Ther Med 2019;17:4230-6.
88. de Las Pozas A, Reiner T, De Cesare V, Trost M, Perez-Stable C. Inhibiting Multiple Deubiquitinases To Reduce Androgen Receptor
Expression In Prostate Cancer Cells. Sci Rep 2018;8:13146.
89. Chauhan D, Tian Z, Nicholson B, Kumar KG, Zhou B, et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis
in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 2012;22:345-58.